Recent Advances in Management of Diabetic Macular Edema

Title:Recent Advances in Management of Diabetic Macular Edema

Volume: 11 Issue: 2

Author(s): Koushik Tripathy, Yog Raj Sharma, Karthikeya R, Rohan Chawla, Varun Gogia, Subodh Kumar Singh, Pradeep Venkatesh and Rajpal Vohra

Affiliation:

Keywords: Aflibercept, aspirin, bevacizumab, diabetic retinopathy, glitazones, iluvien, i-vation, mecamylamine, medidur, midostaurin, nepafenac, ozurdex, PASCAL, ranibizumab, retisert, ruboxistaurin, selective retina therapy (SRT), sorbinil, subthreshold micropulse diode laser photocoagulation, VEGF.

Abstract: Diabetic macular edema (DME) is the leading cause of moderate vision loss in diabetics. Modalities to image and monitor DME have evolved much in the last decade. Systemic control is the most important part of management. Available ocular management options include intravitreal antivascular endothelial growth factor (anti-VEGF) agents, laser, steroids (intravitreal or peribulbar), vitrectomy, topical medications and others. Anti-VEGF agents are increasingly being used in clinical practice with good clinical response and are currently the preferred mode of treatment worldwide.

Cite this article as:

Tripathy Koushik, Sharma Yog Raj, R Karthikeya, Chawla Rohan, Gogia Varun, Kumar Singh Subodh, Venkatesh Pradeep and Vohra Rajpal, Recent Advances in Management of Diabetic Macular Edema, Current Diabetes Reviews 2015; 11 (2) . https://dx.doi.org/10.2174/1573399811999150324120640